Hypertrophic and keloidal scars

Acne Scars: Classification and Treatment

Volumn , Issue , 2009, Pages 11-19

  Miteva, Maria ^a   Romanelli, Paolo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80755147481     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (75)

1. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol 1995; 32(Suppl): S26-30.
2. Rivera AE. Clinical aspects of full-thickness wound healing. Clin Dermatol 2007; 25: 39-48.
3. Nedelec B, Ghahary A, Scott PG, Tredget EE. Control of wound contraction. Basic and clinical features. Hand Clin 2000; 16(2): 289-302.
4. Layton AM, Handerson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994; 19: 303-8.
5. Holland DB, Jeremy AHT, Roberts SG et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol 2004; 150: 72-81.
6. Nassiri M. Woolery-Lloyd H, Ramos S et al. Gene expression profling reveals alteration of caspase 6 and 14 transcripts in normal skin of keloid-prone patients. Arch Dermatol Res 2008; in press.
7. Jacob CI, Dover JS, Kainer MS. Acne scarring: a classification and review of treatment options. J Am Acad Dermatol 2001; 45: 109-17.
8. Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol 2008; 59: 659-76.
9. Friedman PM, Skover GR, Payonk G., Kauvar ANB, Geronemus, RG. 3D in-vivo optical skin imaging for topographical quantitative assessment of non-ablative laser technology. Dermatol Surg 2002; 28: 199-204.
10. Dreno B, Bodokh I, Chivot M et al. ECLA grading: a system of acne classification for every day dermatological practice. Ann Dermatol Venereol 1999; 126: 136-41.
11. Dreno B, Khammari A, Orain N et al. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. Dermatology 2007; 214: 46-51.
12. Goodman GJ, Baron JA. Postacne scarring-a quantitative global scarring grading system. J Cosmet Dermatol 2006; 5: 48-52.
13. Goodman G, Baron JA. Post acne scarring-a qualitative global scarring grading system. Dermatol Surg 2006; 32: 1458-66.
14. English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg 1999; 25: 631-8.
15. Louw L. The keloid phenomenon: progress toward a solution. Clin Anat 2007; 20: 3-14.
16. Alster TS, Tanzi EL. Hypertrophic scars and keloids. Am J Clin Dermatol 2003; 4: 235-43.
17. Ehrlich PH, Desmouliere A, Diegelmann RF et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 1994; 145: 105-13.
18. Murray JC. Scars and keloids. Dermatol Clin 1993; 11: 697-707.
19. Koese O, Waseem A. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg 2008; 34: 336-46.
20. Niessem FP, Spawen HM, Schakwjk J et al. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104: 1435-58.
21. Shaffer RS, Shenefelt PD. Keloids and hypertrophic scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46: S63-97.
22. Datuba-Brown DD. Keloids: a review of the literature. Br J Plast Surg 1990; 43: 70-7.
23. Nakaoka H, Miyachi S, Miki Y. Proliferating activity of dermal fibroblastsin keloids and hypertrophic scars. Acta Derm Venereol (Stockh) 1995; 75: 102-4.
24. Wynn T. Fibrotic disease and the TH1/TH2 paradigm. Nature Rev Immunol 2004; 4: 583-94.
25. Doucet C, Brouty-Boye D, Pottin-Clemenceau C et al. IL-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998; 101: 2129-39.
26. Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Rep Reg 2007; 15: S6-17.
27. Gordon S. Alternative activation of macrophages. Nature Rev Immunol 2003; 3: 23-5.
28. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000; 164: 6406-16.
29. Jagadeesan J, Bayat A. Transforming growth factor beta (TGF b) and kelod disease. Int J Surg 2007; 5: 278-85.
30. Lee T, Chin G, Kim W et al. Expression of transforming growth factor beta 1, 2 and 3 proteins in keloids. Ann Plast Surg 1999; 43: 179-84.
31. Tredget E, Shankowsky H, Pannu R et al. Transforming growth factor beta in thermally injured patients with hypertrophic scars:effects of interferon alpha-2b. Plast Reconstr Surg 1998; 102: 1317-28.
32. Chen W, Fu X, Ge S et al. Ontogeny of expression of transforming growth factor-beta and its receptors and their possible relationship with scarless healing in human fetal skin. Wound Repair Regen 2005; 13: 68-75.
33. Bock O, Yu H, Zitron S et al. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblasts of keloid and hypertrophic scars. Acta Derma-to-Venereol 2005; 85: 216-20.
34. Amadeu T, Braune A, Porto L, Desmouliere A, Costa A. Fibril-lin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen 2004; 12: 169-74.
35. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005; 153: 295-300.
36. Zhang Y, McCluskey K, Fujii K, Wahl L. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF and IL-1beta through prostaglandin-dependent and independent mechanisms. J Immunol 1998; 61: 3071-6.
37. Teofoli P, Barduagni S, Ribuffo M et al. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci 1999; 22: 31-7.
38. Akasaka Y, Fujita K, Ishikawa Y et al. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma. Wound Rep Regen 2001; 9: 501-6.
39. Moulin V, Larochelle S, Langlois C et al. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 2004; 198: 350-8.
40. Tanaka A, Hatoko M, Tada H et al. Expression of p53 family in scars. J Dermatol Sci 2004 34: 17-24.
41. Desmouliere A, Redard M, Darby I et al. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146: 56-66.
42. Moulin V, Larochelle S, Langlois C et al. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 2004; 198: 350-8.
43. Niessen FB, Scalkwjk J, Vos H et al. Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J Pathol 2004; 20: 121-9.
44. Aarabi S, Bhatt KA, Shi Y et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J 2007; 21: 3250-61.
45. Tsau SS, Dover JS, Arndt KA, Kaminer MS. Scar management: keloid, hypertrophic, atrophic and acne scars. Semin Cutan Med Surg 2002; 21: 46-75.
46. Bloemen MC, van der Veer WM, Ulrich MM et al. Prevention and curative management of hypertrophic scar formation. Burns 2008; in press.
47. Mustoe TA, Cooter RD, Gold MH et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-71.
48. Li-Tsang CW, Lau JC, Chan CC. Prevalence of hypertrophic scar formation and its characteristics among the Chinese population. Burns 2005; 31: 610-6.
49. Ahn ST, Monafo WW, Mustoe TA. Topical silicone gel: a new treatment for hypertrophic scars. Surgery 1989; 106: 781-6.
50. Wittenberg GP, Fabian BG, Bogomilsky JL et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone and g.s.i.h.s. treatment., Arch Dermatol Clin 1999; 135: 1049-55.
51. Berman B, Perez OA, Konda S et al. A review on the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic scars and keloid scar treatment and management. Dermatol Surg 2007; 33: 1291-303.
52. Chernoff WG, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic Plast Surg 2007; 31: 495-500.
53. Reno F, Grazianetti P, Cannas M. Effects of mechanical compression on hypertrophic scars: prostaglandin E2 release. Burns 2001; 27: 215-8.
54. Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol 2006; 55: 1024-31.
55. Brissett AE, Sherris DA. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg 2001; 17: 263-72.
56. Grevelink JM, White VR. Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring. Dermatol Surg 1998; 24: 527-30.
57. Har-Shai Y, Amar M, Sabo E. Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast Reconstr Surg 2003; 111: 1841-52.
58. Rusciani L, Rossi G, Bono R. Use of cryotherapy in the treatment of keloids. J Dermatol Surg Oncol 1993; 19: 529-34.
59. Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars. A comprehensive review. Plast Reconstr Surg 1989; 84: 827-37.
60. Akita S, Akino K, Yakabe A et al. Combined surgical excision and radiation therapy for keloid treatment. J Craniofac Surg 2007; 18: 1164-9.
61. Alster TS. Laser treatment of hypertrophic scars, keloids, and striae. Dermatol Clin 1997; 15: 419-29.
62. Bouzari N, Davis SC, Nouri K. Laser treatment of keloids and hypertrophic scars. Int J Dermatol 2007; 46: 80-8.
63. Smit JM, Bauland CG, Wijnberg DS, Spawen PHM. Pulsed dye laser treatment, a review of indications and outcome based on published trials. Br J Plast Surg 2005; 58: 981-7.
64. Dierickx C, Goldman MP, Fitzpatrick RE. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995; 95: 84-90.
65. Alster TS, Kurban AK, Grove GL, Grove MJ, Tan OT. Alteration of argon laser-induced scars by the pulsed dye laser. Lasers Surg Med 1993; 13: 68-373.
66. Lipper GM, Perez M. Nonablative acne scar reduction after a series of treatments with a short-pulsed 1,064-nm neodymium:YAG laser. Dermatol Surg 2006; 32: 998-1006.
67. Berman B, Flores F. The treatment of hypertrophic scars and keloids. Eur J Dermatol 1998; 8: 591-5.
68. Nedelec B, Shankowsky H, Scott PG et al. Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery 2001; 130: 798-808.
69. Wang J, Jiao H, Stewart TL et al. Improvement in postburn hypertrophic scar after treatment with IFN-alpha2b is associated with decreased fibrocytes. J Interferon Cytokine Res 2007; 27: 921-30.
70. Hosnuter M, Payasli C, Isikdemir A, Tekerekoglu B. The effects of onion extract on hypertrophic and keloid scars. J Wound Care 2007; 16: 251-4.
71. Ho WS, Ying SY, Chan PC, Chan HH. Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatol Surg 2006; 32: 891-6.
72. Surh YJ, Na HK. Cyclooxygenase-2 as a putative target for cancer chemoprevention by some anti-inflammatory phytochemicals., in Essential Fatty Acids and Eicosanoids., Huang YS, Lin SJ, Huang PC, ed. AOCS Press: Champaign, Illinois, 2002: 146.
73. Phan TT, See P, Tran E et al. Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol 2003; 148: 544-52.
74. Seo T, Blaner WS, Deckelbaum RJ. Omega-3 fatty acids: Molecular approaches to optimal biological outcomes. Curr Opin Lipidol 2005; 16: 11-8.
75. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin Nutr 2004; 79: 935-45.